Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Clinical Oncology

• Publication date

  2003-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2003.06.108PMID 12637464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of tamoxifen on the endometrium

  2004cited by this paper
• The effect of tamoxifen on the endometrium

  2004cited by this paper
• Tamoxifen for Prevention of Breast Cancer

  2003cited by this paper
• Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.

  2001cited by this paper
• Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.

  2001cited by this paper
• Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.

  2001cited by this paper
• Similarities and distinctions in the mode of action of different classes of antioestrogens.

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Intrauterine 5-Aminolevulinic Acid Induces Selective Endometrial Fluorescence in the Rhesus and Cynomolgus Monkey

  1996cited by this paper
• Selective estrogen receptor modulators: pharmacological profile in the rat uterus.

  1996cited by this paper
• Endometrial carcinoma and tamoxifen: clearing up a controversy.

  1995cited by this paper
• Use of tamoxifen for breast cancer: twenty-eight years later.

  1995cited by this paper
• Risk of endometrial cancer after tamoxifen treatment of breast cancer.

  1994cited by this paper
• Tamoxifen in premenopausal patients with metastatic breast cancer: a review.

  1991cited by this paper
• The international variation in breast cancer rates: An epidemiological assessment

  1991cited by this paper
• Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situ

  1991cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper
• Selecting and Ordering Populations: A New Statistical Methodology

  1977cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975cited by this paper

• Selective Estrogen Receptor Modulators (SERMs): State of the Art

  2019cites this paper
• Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

  2017cites this paper
• Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review.

  2017cites this paper
• Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review.

  2017cites this paper
• Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer

  2014cites this paper
• Selective estrogen receptor modulators: tissue specificity and clinical utility

  2014cites this paper
• Selective estrogen receptor modulators: tissue specificity and clinical utility

  2014cites this paper
• Small Molecule Therapeutics Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer

  2014cites this paper
• Metabolites of Tamoxifen as the Basis of Drug Development

  2013cites this paper
• Nuclear Receptors and Their Selective Pharmacologic Modulators

  2013cites this paper
• Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene

  2012cites this paper
• Emerging Selective Estrogen Receptor Modulators

  2012cites this paper
• Estrogen Receptor Modulators and Down Regulators

  2012cites this paper
• Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development

  2011cites this paper
• Prevention of breast cancer by newer SERMs in the future.

  2011cites this paper
• SERMs: progress and future perspectives.

  2010cites this paper
• Endometrial safety: a key hurdle for selective estrogen receptor modulators in development

  2010cites this paper
• Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass

  2010cites this paper
• Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.

  2009cites this paper
• Current and Emerging Pharmacologic Therapies for the Management of Postmenopausal Osteoporosis

  2009cites this paper
• Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1.

  2009cites this paper
• Pharmacology and clinical applications of selective estrogen receptor modulators

  2009cites this paper
• Structural Modulation of Oxidative Metabolism in Design of Improved Benzothiophene Selective Estrogen Receptor Modulators

  2009cites this paper
• Designing the ideal selective estrogen receptor modulator-an achievable goal?

  2009cites this paper
• Strategies of hormonal prevention.

  2009cites this paper
• Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio.

  2008cites this paper
• Subtype‐Selective Estrogens

  2008cites this paper
• Développement d’outils « biocapteurs/modèle cellulaire » pour l’identification de ligands et l’étude des interactions ADN/protéine et protéines/protéines

  2008cites this paper
• Postmenopausal osteoporosis: an update on current and future therapeutic options

  2007cites this paper
• Arzoxifene: the evidence for its development in the management of breast cancer

  2007influential citation
• The future of the new selective estrogen receptor modulators

  2007cites this paper
• Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.

  2007cites this paper
• Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.

  2007cites this paper
• Chemoprevention of breast cancer with selective oestrogen-receptor modulators

  2007cites this paper
• Beyond raloxifene for the prevention of osteoporosis and breast cancer

  2007cites this paper
• Use of biomarkers for breast cancer risk assessment and prevention.

  2007cites this paper
• New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

  2007cites this paper
• Pure oestrogen antagonists for the treatment of advanced breast cancer.

  2006cites this paper
• Estrogen receptors as therapeutic targets in breast cancer.

  2006cites this paper
• Prevention Trials in Women at Moderate Risk of Breast Cancer

  2006cites this paper
• Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.

  2006influential citation
• Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

  2006cites this paper
• Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'F-DMA, a new benzothiophene selective estrogen receptor modulator.

  2006cites this paper
• Bioactivation of Selective Estrogen Receptor Modulators (SERMs).

  2006cites this paper
• Arzoxifene: the development and clinical outcome of an ideal SERM

  2006cites this paper
• Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

  2006cites this paper
• What can be learned from the levormeloxifene experience?

  2006cites this paper
• Clinical Pharmacology of Selective Estrogen Receptor Modulators (SERMs)

  2006cites this paper
• Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators

  2005cites this paper
• Endocrine treatment options for advanced breast cancer--the role of fulvestrant.

  2005cites this paper
• Breast cancer and sex steroids: Critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer

  2005cites this paper
• Effect of the Selective Estrogen Receptor Modulator Arzoxifene on Repopulation of Hormone-Responsive Breast Cancer Xenografts between Courses of Chemotherapy

  2005cites this paper
• Recent advances in estrogen receptor modulators.

  2005cites this paper
• 1–38 Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

  2005cites this paper
• Selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?

  2005cites this paper
• Lifestyle and medical approaches to cancer prevention.

  2005cites this paper
• Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and downregulators for breast cancer – have they lost their way?

  2005cites this paper
• Selective estrogen-receptor modulators for primary prevention of breast cancer.

  2005cites this paper
• Molecular Mechanisms of Hormonal Activity. II. Kinase Systems. Systems with Intracellular Receptors. Transactivation of STS

  2005cites this paper
• State of the science: molecular classifications of breast cancer for clinical diagnostics.

  2004cites this paper
• Should Tamoxifen Be Used in Breast Cancer Prevention?

  2004cites this paper
• Breast cancer chemoprevention Phase IB evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.

  2004influential citation
• Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator

  2004influential citation
• The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.

  2004cites this paper
• Recent Advances in the Management of Metastatic Breast Cancer

  2004cites this paper
• The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma

  2004cites this paper
• Joyce Ann O'Shaughnessy, MD: A Conversation with the Editor

  2004cites this paper
• A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene.

  2004cites this paper
• The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

  2004cites this paper
• Arzoxifene: A Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer

  2004cites this paper
• Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs)

  2003cites this paper
• Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.

  2003cites this paper
• Arzoxifene Eli Lilly.

  2003cites this paper